Immunotherapy / edited by Aung Naing, Joud Hajjar.
Naing, Aung, editor.; Hajjar, Joud, editor.
2021
RM275
Available Online

Linked e-resources

Linked Resource Online Access
Concurrent users Unlimited
Authorized users Authorized users
Document Delivery Supplied Can lend chapters, not whole ebooks

Details

Title Immunotherapy / edited by Aung Naing, Joud Hajjar.
Edition Fourth edition.
ISBN 9783030793081 (electronic bk.)
3030793087 (electronic bk.)
9783030793074 (print)
DOI https://doi.org/10.1007/978-3-030-79308-1
Published Cham : Springer, 2021.
Language English
Description 1 online resource (viii, 447 pages) : illustrations (some color).
Other Standard Identifiers 10.1007/978-3-030-79308-1 doi
Call Number RM275
Dewey Decimal Classification 615.3/7
Summary The field of immuno-oncology continues to rapidly evolve as new insights to fight and treat cancer emerge. The fourth edition of Immunotherapy provides the most current overview of immuno-oncology in different cancer types and toxicities associated with immunotherapy. While immunotherapy has revolutionized the treatment landscape of several solid malignancies, several challenges still exist. Only a subset of patients derive clinical benefits; some do not respond at all, and others respond initially, only for their disease to progress later. Because these drugs can activate a broad range of immune cells, patients suffer from a unique set of side effects known as immune-related adverse events. As more immunotherapeutic agents are used in the clinic, it is important to provide updates about current and ongoing developments in the field to further research efforts and inform treatment decisions. The fourth edition will have a new focus on strategies to overcome the challenges associated with immunotherapy. Chapters will discuss topics such as biomarkers of response, resistance mechanisms, role of imaging in predicting immune-related adverse events, and management of immune-related adverse events. Written by leading experts conducting cutting-edge research, readers will gain up-to-date knowledge on the current state and future of immunotherapy. .
Access Note Access limited to authorized users.
Digital File Characteristics text file PDF
Source of Description Online resource; title from PDF title page (SpringerLink, viewed January 4, 2022).
Added Author Naing, Aung, editor.
Hajjar, Joud, editor.
Series Advances in experimental medicine and biology ; v. 1342. 2214-8019
Available in Other Form Print version: 9783030793074
Print version: 9783030793098
Linked Resources Online Access
Record Appears in Online Resources > Ebooks
All Resources
Immune System in Action
2. Resistance to Immunotherapy: Mechanisms and Means for Overcoming
3. Immunotherapy for Melanoma
4. Immunotherapy in Lung Cancer: Are the promises of long-term benefit finally met?
5. Landscape of Immunotherapy in Genitourinary Malignancies
6. Immuno-oncology for Gynecologic Malignancies
7. Immunotherapy for Neuro-oncology
8. Immunotherapy in Gastrointestinal Malignancies
9. An update on immune based therapies in acute myeloid leukemia: 2021 and beyond!
10. CAR T-cells
11. Skin Reactions to Immune Checkpoint Inhibitors
12. Immunotherapy Mediated luminal Gastrointestinal toxicities
13. Hepatobiliary and Pancreatic Adverse Events
14. Pulmonary toxicities of immunotherapy
15. Immune checkpoint inhibitors (ICIs) related cardiotoxicity
16. Renal Toxicity
17. Immune-Related Oral, Otologic and Ocular Adverse Events
18. Neurologic Toxicities of Immunotherapy
19. Cancer Imaging in Immunotherapy. .

Browse Subjects

Show more subjects...

Statistics

from
to
Export